Study on the Safety of BMS-986525 Alone and with Nivolumab for Patients with Relapsed or Refractory Small Cell Lung Cancer
Sponsor: Bristol-Myers Squibb
Sponsor score: 60
ClinicalTrials ID:NCT07325136
This clinical trial is testing the safety of a new drug, BMS-986525, both by itself and combined with another drug, Nivolumab, in patients whose small cell lung cancer has returned or did not respond to previous treatments.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The goal of this study is to determine if the new drug BMS-986525 is safe for patients with small cell lung cancer that has either come back after treatment or did not respond to treatment. The study will also look at how safe it is to use BMS-986525 together with Nivolumab, another cancer treatment drug.
Eligibility Criteria
Inclusion Criteria
- Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
- Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
- In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.
Exclusion Criteria
- Participants must not have any untreated CNS metastases.
- Participants must not have an active, known or suspected autoimmune disease.
- Participants must not have had a prior organ or tissue allograft.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Local Institution - 0011 | 48201 | Detroit | Michigan |
| Local Institution - 0026 | 14263 | Buffalo | New York |
| Duke Cancer Institute | 27710 | Durham | North Carolina |
| University Hospitals Cleveland Medical Center | 44106 | Cleveland | Ohio |
| SCRI Oncology Partners | 37203 | Nashville | Tennessee |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.